Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Therapy Insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer

Abstract

Although type 2 diabetes and cancer are major health concerns among the adult population, few studies have directly addressed the relationship between the two, or the impact of diabetes on cancer outcomes. Diabetes and hyperglycemia are associated with an elevated risk of developing pancreatic, liver, colon, breast, and endometrial cancer. When treating cancer patients who have diabetes, clinicians must consider the cardiac, renal, and neurologic complications commonly associated with diabetes. Chemotherapeutic choices and, ultimately, the outcome for cancers may be affected by the avoidance of agents that have been shown to provide the best clinical response and survival in cancer patients without other disease complications. Evidence from population-based studies and clinical trials indicate that hyperglycemic and diabetic patients experience higher mortality and recurrence rates after diagnosis with, and treatment for, cancer. Evidence from the intensive care literature indicates that achieving glucose control leads to better clinical outcomes. If so, continued improvement of cancer outcomes may depend upon improved diabetes control. The association between diabetes and cancer is complex and warrants further study as the general population ages and the magnitude of both health problems continues to grow. Here we consider the influence of diabetes and hyperglycemia on the development, treatment, and long-term outcomes of cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Ko C and Chaudhry S (2002) The need for a multidisciplinary approach to cancer care. J Surg Res 105: 53–57

    Article  Google Scholar 

  2. Rowland J et al. (2004) Cancer survivorship-United States, 1971–2001. MMWR 53: 526–529

    Google Scholar 

  3. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2003. (2004) Rev ed Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention 1–8. [http://www.cdc.gov/diabetes] (accessed 24 July 2004)

  4. Williams RH (2002) Williams Textbook of Endocrinology. Philadelphia: WB Saunders Co.

    Google Scholar 

  5. Poulson J (1997) The management of diabetes in patients with advanced cancer. J Pain Symptom Manage 13: 339–346

    Article  CAS  Google Scholar 

  6. Grimberg A and Cohen P (2000) Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 183: 1–9

    Article  CAS  Google Scholar 

  7. Rajah R et al. (1997) Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272: 12181–12188

    Article  CAS  Google Scholar 

  8. Giovannucci E (2003) Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 35: 694–704

    Article  CAS  Google Scholar 

  9. Saydah SH et al. (2003) Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 157: 1092–1100

    Article  Google Scholar 

  10. Ma J et al. (2004) A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 96: 546–553

    Article  CAS  Google Scholar 

  11. Muti P et al. (2002) Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11: 1361–1368

    CAS  PubMed  Google Scholar 

  12. Hu FB et al. (1999) Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Nat Cancer Inst 91: 542–547

    Article  CAS  Google Scholar 

  13. Nilsen TI and Vatten LJ (2001) Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinemia hypothesis. Br J Cancer 84: 417–422

    Article  CAS  Google Scholar 

  14. Will JC et al. (1998) Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 147: 816–825

    Article  CAS  Google Scholar 

  15. Adami HO et al. (1991) Cancer risk in patients with diabetes mellitus. Cancer Causes Control 2: 307–314

    Article  CAS  Google Scholar 

  16. Calle EE et al. (1998) Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control 9: 403–410

    Article  CAS  Google Scholar 

  17. Chow WH et al. (1995) Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst 87: 930–931

    Article  CAS  Google Scholar 

  18. Wideroff L et al. (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89: 1360–1365

    Article  CAS  Google Scholar 

  19. Lagiou P et al. (2000) Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 92: 1096–1099

    Article  CAS  Google Scholar 

  20. Michels KB et al. (2003) Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 26: 1752–1758

    Article  Google Scholar 

  21. Weiderpass E et al. (2002) Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 102: 258–261

    Article  CAS  Google Scholar 

  22. Zendehdel K et al. (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Nat Cancer Inst 95: 1797–1800

    Article  Google Scholar 

  23. Wildiers H et al. (2003) Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 42: 1213–1242

    Article  CAS  Google Scholar 

  24. Verstappen CC et al. (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63: 1549–1563

    Article  CAS  Google Scholar 

  25. Bonadonna G and Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10–15

    Article  CAS  Google Scholar 

  26. De Vita VT Jr et al. (1987) The chemotherapy of lymphomas: looking back, moving forward—the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 47: 5810–5824

    PubMed  Google Scholar 

  27. Schilsky RL (1982) Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol 9: 75–83

    CAS  PubMed  Google Scholar 

  28. Nichols CR (1998) Testicular cancer. Curr Probl Cancer 22: 187–274

    Article  CAS  Google Scholar 

  29. Nesto RW (2003) The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med 4 (Suppl 6): 511–518

    Google Scholar 

  30. Avogaro A et al. (2004) Diabetic cardiomyopathy: a metabolic perspective. Am J Cardiol 93: 13A–16A

    Article  CAS  Google Scholar 

  31. Theodoulou M and Seidman AD (2003) Cardiac effects of adjuvant therapy for early breast cancer. Semin Oncol 30: 730–739

    Article  CAS  Google Scholar 

  32. Donnelly R et al. (2000) ABC of arterial and venous disease: vascular complications of diabetes. BMJ 320: 1062–1066

    Article  CAS  Google Scholar 

  33. Vokes EE et al. (1993) Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol 11: 360–368

    Article  CAS  Google Scholar 

  34. Weiser MA et al. (2004) Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 100: 1179–1185

    Article  CAS  Google Scholar 

  35. Meyerhardt JA et al. (2003) Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 21: 433–440

    Article  Google Scholar 

  36. Bertoni AG et al. (2001) Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care 24: 1044–1049

    Article  CAS  Google Scholar 

  37. Ellis ME et al. (1986) Hyperglycemic complications associated with adjuvant chemotherapy of breast cancer. A cancer and leukemia group B (CALGB) study. Am J Clin Oncol 9: 533–536

    Article  CAS  Google Scholar 

  38. Levetan CS et al. (1998) Unrecognized diabetes among hospitalized patients. Diabetes Care 21: 246–249

    Article  CAS  Google Scholar 

  39. Sawin C and McCulloch D (online 5 November 2004) Management of diabetes mellitus in the acute care setting. [http://www.uptodate.com] (accessed 29 November 2004)

  40. Levetan CS et al. (1995) Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes. Am J Med 99: 22–28

    Article  CAS  Google Scholar 

  41. Harris MI and Eastman RC (2000) Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes Metab Res Rev 16: 230–236

    Article  CAS  Google Scholar 

  42. Coughlin SS et al. (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159: 1160–1167

    Article  Google Scholar 

  43. Verlato G et al. (2003) Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 26: 1047–1051

    Article  Google Scholar 

  44. Goodwin PJ et al. (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20: 42–51

    Article  CAS  Google Scholar 

  45. Gurney H (2002) How to calculate the dose of chemotherapy. BJC 86: 1297–1302

    Article  CAS  Google Scholar 

  46. Hewitt M et al. (2003) Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci 58: 82–91

    Article  Google Scholar 

  47. Yancik R et al. (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285: 885–892

    Article  CAS  Google Scholar 

  48. Krinsley JS (2003) Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 78: 1471–1478

    Article  Google Scholar 

  49. Saydah SH et al. (2001) Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care 24: 447–453

    Article  CAS  Google Scholar 

  50. Shaw JE et al. (1999) Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42: 1050–1054

    Article  CAS  Google Scholar 

  51. Eyre H et al. (2004) Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. CA Cancer J Clin 54: 190–207

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lisa C Richardson.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Richardson, L., Pollack, L. Therapy Insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Rev Clin Oncol 2, 48–53 (2005). https://doi.org/10.1038/ncponc0062

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0062

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing